Trials / Completed
CompletedNCT02303873
Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Alendronate should be considered as an alternative therapy of osteogenesis imperfecta (OI) because it significantly increased areal bone mineral density (BMD) and its Z score, decreased fracture incidence, inhibited bone resorption biomarkers. Alendronate exerted beneficial roles in different age brackets, especially in young patients with OI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alendronate | Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.). |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2011-07-01
- Completion
- 2014-08-01
- First posted
- 2014-12-01
- Last updated
- 2014-12-10
Source: ClinicalTrials.gov record NCT02303873. Inclusion in this directory is not an endorsement.